CO4650042A1 - Derivados de 6-fenilpiridil-2-amina - Google Patents

Derivados de 6-fenilpiridil-2-amina

Info

Publication number
CO4650042A1
CO4650042A1 CO97015141A CO97015141A CO4650042A1 CO 4650042 A1 CO4650042 A1 CO 4650042A1 CO 97015141 A CO97015141 A CO 97015141A CO 97015141 A CO97015141 A CO 97015141A CO 4650042 A1 CO4650042 A1 CO 4650042A1
Authority
CO
Colombia
Prior art keywords
alkyl
phenyl
independently selected
aryl
ring
Prior art date
Application number
CO97015141A
Other languages
English (en)
Inventor
Lowe John Adams
Peter John Whittle
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO4650042A1 publication Critical patent/CO4650042A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a ciertos derivados de 6-fenil-piridin-2-ilamina que presentan actividad como inhibidores de la óxido nítrico sintasa (NOS), a composiciones farmacéuticas que los contienen y a su uso en el tratamiento y prevención de trastornos del sistema nervioso central.Un compuesto de la fórmulay las sales farmacéuticamente aceptables del mismo, en la que R1 y R2 se seleccionan, independientemente, entre alquilo (Cl -C6 ), tetrahidronaftaleno y aralquilo, donde el radical arilo de dicho aralquilo es fenilo o naftilo y donde dicho alquilo (C1 -C6 ), dicho grupo tetrahidronaftaleno o el anillo arilo de dicho grupo aralquilo opcionalmente puede estar sustituido con uno a tres sustituyentes que se seleccionan, independientemente, entre halo, nitro, hidroxi, ciano, amino, alcoxi (C1 -C4 ) y alquilamino (C1 -C4 ); o R1 y R2 forman, junto con el nitrógeno al que están unidos, un anillo de piperazina, piperidina o pirrolidina o un anillo azabicíclico que contiene de 6 a 14 miembros en el anillo, de los cuales de 1 a 3 son nitrógenos y el resto son carbonos; y donde dichos anillos de piperazina, piperidina y pirrolidina opcionalmente pueden estar sustituidos con uno más sustituyentes;n es 0, 1 ó 2; m es O, 1 ó 2; cada R8 y cada R9 se seleccionan, independientemente, entre alquilo(C1 -C4 ) y aril-alquilo(C1 -C4 ), donde dicho arilo se selecciona entre fenilo y naftilo; alilo y fenalilo; X e Y se seleccionan, independientemente, entre metilo, metoxi, hidroxi e hidrógeno; y R10 es alquilo (C1 -C6 );con la condición de que R8 esté ausente cuando n es cero y R9 esté ausente cuando m es cero; o una sal farmacéuticamente aceptable de tal compuesto.
CO97015141A 1996-03-29 1997-03-20 Derivados de 6-fenilpiridil-2-amina CO4650042A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1434396P 1996-03-29 1996-03-29

Publications (1)

Publication Number Publication Date
CO4650042A1 true CO4650042A1 (es) 1998-09-03

Family

ID=21764907

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97015141A CO4650042A1 (es) 1996-03-29 1997-03-20 Derivados de 6-fenilpiridil-2-amina

Country Status (44)

Country Link
US (2) US6235747B1 (es)
EP (2) EP0891332B1 (es)
JP (1) JP3455229B2 (es)
KR (1) KR100313641B1 (es)
CN (2) CN1546470A (es)
AP (1) AP677A (es)
AR (1) AR006391A1 (es)
AT (1) ATE261942T1 (es)
AU (1) AU729129B2 (es)
BG (1) BG64310B1 (es)
BR (1) BR9708386A (es)
CA (1) CA2250372C (es)
CO (1) CO4650042A1 (es)
CZ (1) CZ291647B6 (es)
DE (1) DE69728138T2 (es)
DK (1) DK0891332T3 (es)
DZ (1) DZ2197A1 (es)
EA (1) EA002270B1 (es)
ES (1) ES2214604T3 (es)
GT (1) GT199700033A (es)
HK (1) HK1018780A1 (es)
HR (1) HRP970174B1 (es)
HU (1) HUP9902455A3 (es)
ID (1) ID17116A (es)
IL (1) IL125811A (es)
IS (1) IS4823A (es)
MA (1) MA26424A1 (es)
MY (1) MY118283A (es)
NO (1) NO312460B1 (es)
NZ (2) NZ326874A (es)
OA (1) OA10873A (es)
PE (1) PE55098A1 (es)
PL (1) PL329195A1 (es)
PT (1) PT891332E (es)
SI (1) SI0891332T1 (es)
SK (1) SK113998A3 (es)
TN (1) TNSN97055A1 (es)
TR (1) TR199801930T2 (es)
TW (1) TW438793B (es)
UA (1) UA49006C2 (es)
UY (1) UY24503A1 (es)
WO (1) WO1997036871A1 (es)
YU (1) YU12097A (es)
ZA (1) ZA972689B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL329195A1 (en) * 1996-03-29 1999-03-15 Pfizer Derivatives of 6-phenylpyridol-2-amine
HN1997000027A (es) 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina
ES2224354T3 (es) * 1997-02-10 2005-03-01 Pfizer Products Inc. Piridinas 2-amino-6-(4-fenoxi-2-sustituido)sustituidas.
HN1998000118A (es) * 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
HN1998000125A (es) * 1997-08-28 1999-02-09 Pfizer Prod Inc 2-aminopiridinas con sustituyentes alcoxi ramificados
DE19806348A1 (de) * 1998-02-12 1999-08-19 Schering Ag 3,4-Dihydrochinolin-Derivate und ihre Verwendung in Arzneimitteln
PL344699A1 (en) * 1998-06-03 2001-11-19 Pfizer Prod Inc 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors
AR019190A1 (es) * 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
BR9912906A (pt) * 1998-08-11 2001-05-08 Pfizer Prod Inc Usos farmacêuticos para inibidores de nos
DE19845830A1 (de) * 1998-09-24 2000-03-30 Schering Ag Aminoalkyl-3,4-dihydrochinolin-Derivate und ihre Verwendung in Arzneimitteln
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
SE9803710L (sv) 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
SE9803518D0 (sv) * 1998-10-15 1998-10-15 Astra Pharma Prod Novel compounds
DE59911958D1 (de) 1998-11-13 2005-05-25 Schering Ag Fluorierte 3,4-dihydrochinolin-derivative als nos-inhibitoren
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
ATE277905T1 (de) 1999-02-24 2004-10-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
CZ20013036A3 (cs) * 1999-02-25 2002-03-13 Pfizer Products Inc. 2-aminopyridiny obsahující jako substituenty kondenzované kruhové skupiny
US6344358B1 (en) * 1999-05-28 2002-02-05 Fujisawa Pharmaceutical Co., Ltd. Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
SE9904765D0 (sv) 1999-12-23 1999-12-23 Astra Ab Pharmaceutically-useful compounds
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
WO2002083673A1 (en) 2001-04-10 2002-10-24 Ortho-Mcneil Pharmaceutical, Inc. 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
US20030232739A1 (en) * 2001-08-15 2003-12-18 Pfizer Inc. Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
US6514960B1 (en) 2001-08-27 2003-02-04 Hedonist Biochemical Technologies Co., Ltd. Use of bismuth subgallate in inhibition of production of nitric oxide synthase
US20040077853A1 (en) * 2001-10-10 2004-04-22 Pfizer Inc. 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
DOP2002000467A (es) * 2001-10-10 2003-04-15 Pfizer Prod Inc 2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas
US6803470B2 (en) 2001-10-10 2004-10-12 Pfizer Inc 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
WO2003092693A1 (en) * 2002-05-06 2003-11-13 Washington University Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
GB0218326D0 (en) * 2002-08-07 2002-09-11 Glaxo Group Ltd Compounds
CN100402529C (zh) 2002-09-09 2008-07-16 詹森药业有限公司 用于治疗orl-1受体介导疾病的羟基烷基取代的1,3,8-三氮杂螺[4,5]癸-4-酮衍生物
EP1572648B1 (en) * 2002-12-10 2008-07-09 Ranbaxy Laboratories, Ltd. 3,6-disubstituted azabicyclo (3.1.0)-hexane derivatives as muscarinic receptor antagonists
US7288658B2 (en) 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
WO2005007627A1 (ja) * 2003-07-18 2005-01-27 Nihon Nohyaku Co., Ltd. フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤
NZ546012A (en) * 2003-10-14 2009-12-24 Pfizer Prod Inc Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
SG160342A1 (en) * 2005-02-21 2010-04-29 Proximagen Ltd Inhibition or treatment of dyskinesia
ES2361932T3 (es) * 2005-05-17 2011-06-24 Santen Pharmaceutical Co., Ltd. Inhibidor de angiogénesis que contiene un derivado de amina como ingrediente activo.
EP2119440A1 (en) * 2005-05-17 2009-11-18 Santen Pharmaceutical Co., Ltd. Amidino derivatives for use in the prevention or treatment of retinitis pigmentosa and Leber's disease
ES2335922T3 (es) 2005-09-23 2010-04-06 F.Hoffmann-La Roche Ag Nueva formulacion de dosificacion.
EP2027087A2 (en) * 2006-05-18 2009-02-25 MannKind Corporation Intracellular kinase inhibitors
WO2008067167A1 (en) 2006-11-28 2008-06-05 Janssen Pharmaceutica N.V. Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
WO2008124209A1 (en) 2007-04-09 2008-10-16 Janssen Pharmaceutica, N.V. 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
WO2009076142A2 (en) * 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2012042539A2 (en) 2010-09-28 2012-04-05 Panacea Biotec Ltd Novel bicyclic compounds
US20130281702A1 (en) * 2012-04-24 2013-10-24 Jonathan P. Pease Methods For Preparing Fentanyl And Fentanyl Intermediates
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
KR101612179B1 (ko) * 2013-04-19 2016-04-12 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
US10759791B2 (en) * 2014-11-04 2020-09-01 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
EP3509588B1 (en) 2016-09-12 2023-06-07 Integral Health,Inc. Bicyclic compounds useful as gpr120 modulators
WO2018049324A1 (en) * 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP3589627A4 (en) 2017-02-28 2020-08-05 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V) (BETA-6) -INTEGRIN
PE20211640A1 (es) 2018-08-29 2021-08-24 Morphic Therapeutic Inc INHIBICION DE LA INTEGRINA xvß6

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK40192D0 (da) * 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
DE4241801A1 (de) * 1992-12-11 1994-06-16 Bernhard Icking Vorrichtung zum Aufschluß von stärke- und/oder zuckerhaltigen Rohstoffen
EP0674627A1 (en) * 1992-12-18 1995-10-04 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
JPH09504028A (ja) * 1993-10-21 1997-04-22 ジー．ディー．サール アンド カンパニー 酸化窒素シンターゼ抑制剤として有用なアミジノ誘導体
US5629322A (en) * 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
WO1996018616A1 (en) * 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
PL329195A1 (en) * 1996-03-29 1999-03-15 Pfizer Derivatives of 6-phenylpyridol-2-amine
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina

Also Published As

Publication number Publication date
NZ326874A (en) 2000-01-28
HUP9902455A3 (en) 2000-06-28
UY24503A1 (es) 2000-09-29
DE69728138T2 (de) 2004-09-16
NO984516D0 (no) 1998-09-28
EA002270B1 (ru) 2002-02-28
BR9708386A (pt) 1999-08-03
KR100313641B1 (ko) 2002-02-19
AP9700954A0 (en) 1997-04-30
EP0891332B1 (en) 2004-03-17
PT891332E (pt) 2004-07-30
HRP970174A2 (en) 2000-12-31
MY118283A (en) 2004-09-30
ATE261942T1 (de) 2004-04-15
CN1168719C (zh) 2004-09-29
NZ500927A (en) 2004-11-26
ZA972689B (en) 1998-09-28
CA2250372A1 (en) 1997-10-09
BG102872A (en) 1999-11-30
CZ261498A3 (cs) 1999-08-11
IL125811A (en) 2003-01-12
HK1018780A1 (en) 2000-01-07
SI0891332T1 (en) 2004-06-30
ID17116A (id) 1997-12-04
CZ291647B6 (cs) 2003-04-16
IS4823A (is) 1998-08-13
US6235747B1 (en) 2001-05-22
IL125811A0 (en) 1999-04-11
TW438793B (en) 2001-06-07
MA26424A1 (fr) 2004-12-20
CA2250372C (en) 2005-06-21
TNSN97055A1 (fr) 2005-03-15
KR20000005127A (ko) 2000-01-25
EA199800772A1 (ru) 1999-04-29
JPH11510513A (ja) 1999-09-14
NO312460B1 (no) 2002-05-13
OA10873A (en) 2001-09-27
YU12097A (en) 1999-11-22
AR006391A1 (es) 1999-08-25
US6465491B2 (en) 2002-10-15
AP677A (en) 1998-09-25
EP0891332A1 (en) 1999-01-20
PE55098A1 (es) 1998-10-07
ES2214604T3 (es) 2004-09-16
GT199700033A (es) 1998-09-10
DE69728138D1 (de) 2004-04-22
SK113998A3 (en) 2001-05-10
CN1215391A (zh) 1999-04-28
AU729129B2 (en) 2001-01-25
DK0891332T3 (da) 2004-07-05
US20010034348A1 (en) 2001-10-25
AU1554897A (en) 1997-10-22
EP1471055A1 (en) 2004-10-27
UA49006C2 (uk) 2002-09-16
TR199801930T2 (xx) 1998-12-21
HUP9902455A2 (hu) 1999-11-29
HRP970174B1 (en) 2002-06-30
JP3455229B2 (ja) 2003-10-14
BG64310B1 (bg) 2004-09-30
WO1997036871A1 (en) 1997-10-09
DZ2197A1 (fr) 2002-12-02
CN1546470A (zh) 2004-11-17
NO984516L (no) 1998-09-28
PL329195A1 (en) 1999-03-15

Similar Documents

Publication Publication Date Title
CO4650042A1 (es) Derivados de 6-fenilpiridil-2-amina
NZ502281A (en) 2-aminopyridines containing fused ring substituents as nitric oxide synthase (NOS) inhibitors
AR010331A1 (es) Compuestos derivados de 6-fenilpiridil-2-amina utiles como inhibidores nos, composiciones farmaceuticas que comprenden dichos compuestos, y metodosde tratamiento utilizando dichos compuestos.
CO4970713A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
AR025735A1 (es) Compuestos terapeuticos
AR011117A1 (es) 2-amino-6-(4-fenoxi-2-sustituido)-piridinas sustituidas, composiciones farmaceuticas que las contienen, compuestos intermediarios para producirlas y uso de los compuestos en la preparacion de medicamentos.
CO5261632A1 (es) Inhibidores de la recaptacion de monoamidas para el tratamiento del snc
AR013094A1 (es) Compuestos de urea n-sustituida,composicion farmaceutica y uso de dichos compuestos para preparar medicamentos
CO4900050A1 (es) Pirrolcarboxanilidas fusionadas; una nueva clase de ligan- dos receptores cerebrales de gaba
IE891797L (en) 4-amino quinolines and naphthyridines, process for their¹preparation and their use as medicines
ES2188194T3 (es) 1,8-naftiridin-4(1h)-onas sustituidas como inhibidores de la fosfodiesterasa 4.
AR003126A1 (es) Nuevos derivados de la camptotecina sustituidos que poseen actividad antitumoral, un procedimiento para su preparacion, y composicionesfarmaceuticas que los contienen.
HUP0002803A2 (hu) NOS Gátló hatású, elágazó szénláncú, alkoxi-csoporttal helyettesített 2-amino-piridinek
ECSP930953A (es) Nuevos derivados de indol
CO5160242A1 (es) UTILIZACION DE DERIVADOS DE PIRIDAZINO [4,5-b] INDOL-1- ACETAMIDA, PARA LA PREPARACION DE MEDICAMENTOS DESTINADOS A LAS ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL
AR033942A1 (es) Compuestos de monofluoroalquilo aplicables en la potenciacion de los compuestos intermediarios utilizables en la sintesis de dichos compuestos de monofluoralquilo; composiciones farmaceuticas formuladas con dichos compuestos potenciadores y metodos para la potenciacion de las funciones de dichos rec
MX9306310A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2154453T3 (es) Compuestos pertenecientes a la familia de los amidiniums, composiciones farmaceuticas que les contienen y sus aplicaciones.
BG105855A (en) 2-aminopyridines containing fused ring substituents
DK219488A (da) Benzo- og thieno-3,4-dihydropyridinderivater, deres fremstilling og laegemidler indeholdende forbindelserne
ES2172376B1 (es) Nuevos derivados de isoquinoleinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos
AR021970A1 (es) Inhibidores de proteasas
AR017260A1 (es) Derivados de eritromicina 6-0-sustituida de 3-descladinosa, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento y procedimiento para su preparacion
ES2188515T3 (es) Derivados de 22r-hidroxicolesta-8,14-dieno con actividad inhibidora de la meiosis.